These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 11936564)

  • 41. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M; Chang S; Hellriegel ET
    Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.
    Purkins L; Wood N; Ghahramani P; Kleinermans D; Layton G; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):30-6. PubMed ID: 14616411
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of fluconazole on the pharmacokinetics of rosuvastatin.
    Cooper KJ; Martin PD; Dane AL; Warwick MJ; Schneck DW; Cantarini MV
    Eur J Clin Pharmacol; 2002 Nov; 58(8):527-31. PubMed ID: 12451430
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.
    Walsh TJ; Driscoll T; Milligan PA; Wood ND; Schlamm H; Groll AH; Jafri H; Arrieta AC; Klein NJ; Lutsar I
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4116-23. PubMed ID: 20660687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis.
    Queiroz-Telles F; Goldani LZ; Schlamm HT; Goodrich JM; Espinel-Ingroff A; Shikanai-Yasuda MA
    Clin Infect Dis; 2007 Dec; 45(11):1462-9. PubMed ID: 17990229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
    Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
    Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
    Keirns J; Sawamoto T; Holum M; Buell D; Wisemandle W; Alak A
    Antimicrob Agents Chemother; 2007 Feb; 51(2):787-90. PubMed ID: 17116670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing.
    Passler NH; Chan HM; Stewart AJ; Duran SH; Welles EG; Lin HC; Ravis WR
    J Vet Pharmacol Ther; 2010 Feb; 33(1):35-41. PubMed ID: 20444023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
    Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3225-32. PubMed ID: 20547816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Steady-state pharmacokinetics and metabolism of voriconazole in patients.
    Geist MJ; Egerer G; Burhenne J; Riedel KD; Weiss J; Mikus G
    J Antimicrob Chemother; 2013 Nov; 68(11):2592-9. PubMed ID: 23766489
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
    Liu P; Foster G; LaBadie RR; Gutierrez MJ; Sharma A
    J Clin Pharmacol; 2008 Jan; 48(1):73-84. PubMed ID: 18025525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.
    Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH
    Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of rizatriptan in healthy elderly subjects.
    Musson DG; Birk KL; Panebianco DL; Gagliano KD; Rogers JD; Goldberg MR
    Int J Clin Pharmacol Ther; 2001 Oct; 39(10):447-52. PubMed ID: 11680669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
    Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
    J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
    Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration.
    Radej J; Krouzecky A; Stehlik P; Sykora R; Chvojka J; Karvunidis T; Novak I; Matejovic M
    Ther Drug Monit; 2011 Aug; 33(4):393-7. PubMed ID: 21654349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
    Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
    J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic/pharmacodynamic profile of voriconazole.
    Theuretzbacher U; Ihle F; Derendorf H
    Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.